PFE – Pfizer Inc.

Latest News & Stock Analysis

Pfizer Inc. (PFE) is a global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide. Its diverse portfolio includes medicines and vaccines, covering a wide range of therapeutic areas such as oncology, cardiovascular, and immunology. Pfizer’s business model focuses on research and development of innovative therapies, strategic acquisitions, and partnerships to address unmet medical needs. The company is renowned for its blockbuster drugs and its significant role in developing and distributing vaccines, including its groundbreaking mRNA COVID-19 vaccine. Investors interested in pharmaceutical stocks often look to Pfizer for its stability, dividend payouts, and potential for growth through its robust pipeline of new drugs. Stay updated with the latest news on PFE, market trends, and in-depth stock analysis to make informed investment decisions.

Pfizer Halts Weight-Loss Drug Trial: What It Means for PFE
PFE

Pfizer Halts Weight-Loss Drug Trial: What It Means for PFE

by | 14/04/2025 04:00 AM | PFE

💊 Pfizer has stopped the development of its daily weight-loss pill, Danuglipron, after a patient experienced potential drug-induced liver injury during a trial.

📉 Despite the setback, Pfizer states its commitment to advancing other promising programs in its pipeline.

📊 The stock showed volatility but recovered. Valuation metrics like a low forward P/E (around 7) and a high dividend yield (nearly 8%) are noted amidst the news.

Read more!